Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

157 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Estrogen Receptor Beta (ERβ): A Ligand Activated Tumor Suppressor.
Mal R, Magner A, David J, Datta J, Vallabhaneni M, Kassem M, Manouchehri J, Willingham N, Stover D, Vandeusen J, Sardesai S, Williams N, Wesolowski R, Lustberg M, Ganju RK, Ramaswamy B, Cherian MA. Mal R, et al. Among authors: wesolowski r. Front Oncol. 2020 Oct 23;10:587386. doi: 10.3389/fonc.2020.587386. eCollection 2020. Front Oncol. 2020. PMID: 33194742 Free PMC article. Review.
Severe and prolonged lymphopenia observed in patients treated with bendamustine and erlotinib for metastatic triple negative breast cancer.
Layman RM, Ruppert AS, Lynn M, Mrozek E, Ramaswamy B, Lustberg MB, Wesolowski R, Ottman S, Carothers S, Bingman A, Reinbolt R, Kraut EH, Shapiro CL. Layman RM, et al. Among authors: wesolowski r. Cancer Chemother Pharmacol. 2013 May;71(5):1183-90. doi: 10.1007/s00280-013-2112-2. Epub 2013 Feb 21. Cancer Chemother Pharmacol. 2013. PMID: 23430121 Free PMC article. Clinical Trial.
Pilot study on the efficacy of an ondansetron- versus palonosetron-containing antiemetic regimen prior to highly emetogenic chemotherapy.
Wenzell CM, Berger MJ, Blazer MA, Crawford BS, Griffith NL, Wesolowski R, Lustberg MB, Phillips GS, Ramaswamy B, Mrozek E, Flynn JM, Shapiro CL, Layman RM. Wenzell CM, et al. Among authors: wesolowski r. Support Care Cancer. 2013 Oct;21(10):2845-51. doi: 10.1007/s00520-013-1865-9. Epub 2013 Jun 8. Support Care Cancer. 2013. PMID: 23748485 Free PMC article. Clinical Trial.
Treatment-related mortality with everolimus in cancer patients.
Wesolowski R, Abdel-Rasoul M, Lustberg M, Paskell M, Shapiro CL, Macrae ER. Wesolowski R, et al. Oncologist. 2014 Jun;19(6):661-8. doi: 10.1634/theoncologist.2013-0355. Epub 2014 May 2. Oncologist. 2014. PMID: 24794158 Free PMC article.
Stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction.
Berger MJ, Vargo C, Vincent M, Shaver K, Phillips G, Layman R, Macrae E, Mrozek E, Ramaswamy B, Wesolowski R, Shapiro CL, Lustberg MB. Berger MJ, et al. Among authors: wesolowski r. Support Care Cancer. 2015 Jul;23(7):2019-24. doi: 10.1007/s00520-014-2556-x. Epub 2014 Dec 18. Support Care Cancer. 2015. PMID: 25519756 Free PMC article.
Neoadjuvant dual HER2-targeted therapy with lapatinib and trastuzumab improves pathologic complete response in patients with early stage HER2-positive breast cancer: a meta-analysis of randomized prospective clinical trials.
Hicks M, Macrae ER, Abdel-Rasoul M, Layman R, Friedman S, Querry J, Lustberg M, Ramaswamy B, Mrozek E, Shapiro C, Wesolowski R. Hicks M, et al. Among authors: wesolowski r. Oncologist. 2015 Apr;20(4):337-43. doi: 10.1634/theoncologist.2014-0334. Epub 2015 Mar 2. Oncologist. 2015. PMID: 25732265 Free PMC article.
157 results